...
首页> 外文期刊>The Journal of Immunology: Official Journal of the American Association of Immunologists >Chemokines and T lymphocyte activation: II. Facilitation of human T cell trafficking in severe combined immunodeficiency mice.
【24h】

Chemokines and T lymphocyte activation: II. Facilitation of human T cell trafficking in severe combined immunodeficiency mice.

机译:趋化因子和 T 淋巴细胞活化:II.促进严重联合免疫缺陷小鼠中人类T细胞运输。

获取原文
获取原文并翻译 | 示例
           

摘要

Previous studies from this laboratory have demonstrated that the chemokines RANTES (recombinant human regulated upon activation, normally T cell expressed and presumably secreted), macrophage chemotactic peptide-1, recombinant human macrophage inflammatory protein-1 alpha (rhMIP-1 alpha) IL-8, and IP-10 are capable of inducing human T cell infiltration into the injection site of severe combined immunodeficiency (SCID) mice reconstituted with human PBL. However, the ability of these chemokines to facilitate T cell homing into various lymphoid tissues has not been examined. Initial studies focused on the ability of rhMIP-1 beta to induce human T cell infiltration into injection sites in human PBL-SCID mice. SCID mice received s.c. injections of rhMIP-1 beta or PBS (1 microgram/injection) in the hindflank for 4 h or sequential injections for 3 days. Biopsies of the MIP-1 beta injection site revealed the presence of significant mononuclear cell accumulation 72 h after injection. Immunohistologic evaluationdetermined that significant numbers of human CD3+ T cells were recruited in response to MIP-1 beta injections, and this infiltration could be specifically blocked by co-administration of anti-MIP-1 beta antiserum. We subsequently examined these chemokine-injected mice for the effect of trafficking of human T cells to peripheral lymphoid organs. Flow cytometric analysis of the thymus in human PBL-SCID mice revealed that treatment with rhMIP-1 beta or rhRANTES, but not platelet factor-4, resulted in improved thymic homing of the human T cells after 72 h. This trafficking effect was shown to be direct, as pretreatment of the human T cells with the chemokines in vitro also improved peripheral lymphoid trafficking of the human cells. In addition, co-injection of rhMIP-1 beta with anti-1 beta antiserum abrogated the increase in T cell homing to the thymus. These data demonstrate that MIP-1 beta and RANTES directly augment human T cell trafficking to peripheral murine lymphoid tissues. Chemokines may, therefore, under either isogeneic or xenogeneic conditions, play a role in normal lymphocyte recirculation and homing, and may be of potential clinical use in promoting immune cell trafficking and function.
机译:该实验室先前的研究表明,趋化因子 RANTES(重组人激活后受到调节,正常 T 细胞表达并可能分泌)、巨噬细胞趋化肽-1、重组人巨噬细胞炎症蛋白-1 α (rhMIP-1 α) IL-8 和 IP-10 能够诱导人 T 细胞浸润到与人 PBL 重组的严重联合免疫缺陷 (SCID) 小鼠的注射部位。然而,这些趋化因子促进 T 细胞归巢到各种淋巴组织的能力尚未得到检验。初步研究集中在rhMIP-1 β诱导人T细胞浸润到人PBL-SCID小鼠注射部位的能力。SCID小鼠在后侧皮下注射rhMIP-1β或PBS(1μg/注射)4小时或连续注射3天。MIP-1 β 注射部位的活检显示注射后 72 小时存在显着的单核细胞积累。免疫组织学评估确定,MIP-1 β 注射后募集了大量人 CD3+ T 细胞,并且可以通过联合施用抗 MIP-1 β 抗血清来特异性阻断这种浸润。随后,我们检查了这些注射趋化因子的小鼠,以了解人类T细胞运输到外周淋巴器官的影响。人PBL-SCID小鼠胸腺的流式细胞术分析显示,用rhMIP-1β或rhRANTES处理,而不是血小板因子-4,导致72小时后人T细胞的胸腺归巢得到改善。这种运输效应被证明是直接的,因为在体外用趋化因子预处理人类T细胞也改善了人类细胞的外周淋巴运输。此外,rhMIP-1 β 与抗 1 β 抗血清共同注射消除了 T 细胞归巢到胸腺的增加。这些数据表明,MIP-1 β 和 RANTES 直接增强了人 T 细胞向外周小鼠淋巴组织的运输。因此,趋化因子可能在同基因或异种条件下,在正常淋巴细胞再循环和归巢中发挥作用,并可能在促进免疫细胞运输和功能方面具有潜在的临床用途。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号